Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
bearish
Shanghai Haohai Biological Tec
Watchlist
Shanghai Haohai Biological Technology (688366CH)- Diversified Business Layout Doesn't Secure Outlook
Equity Bottom-Up
375 Views
19 May 2022 00:43
Haohai builds diversified business via M&A,but none is growth point with high certainty. Its medical aesthetics has no obvious advantage and the valuation would be lower due to centralized procurement
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »
Quiddity CSI Medical Jun25 Results: 6 ADDs/DELs Confirmed; US$286mn One-Way Flows
Quiddity Leaderboard CSI Medical Jun25: Three ADDs/DELs Likely; US$146mn One-Way; 1x-5x ADV
China Healthcare Weekly (March.3) - TCM New Policy, Pfizer to Acquire Seagen, Haohai Biological
Shanghai Haohai Biological Technology (688366CH)- Diversified Business Layout Doesn't Secure Outlook
Trending Collections
More »
Japan
Event-Driven
Equity Bottom-Up
Sell / Short Ideas
India
Asia Event-Driven
Asia ECM
South Korea
Unpaywalled Insights
Philippines
Trending Insights
More »
Dickson Concepts (113 HK): A Necessary HK Arbageddon
HEW: Inflation Persists, But Cuts Loom
NSDL Vs CDSL: A Bottom-Up Comparison
[Japan Activism] Mitsui Matsushima (1518 JP) Buyback Tender - Surprising Results and Implications
TSMC (2330.TT) Outlook Post Strong Q2: Our Model Says "EXTREME OVERBOUGHT CONDITION"
Top Unpaywalled Insights
More »
[IO Technicals 2025/29] Near Term Bullish Trend to Persist
Veon's (Nasdaq: VEON) Subsidiary Kyivstar Eyes Nasdaq Listing
Reimagining Venture Capital Through Impact Investing | Chris Maher on Disability Innovation
[IO Technicals 2025/28] Bullish Momentum Intensifies
Mid-Year Themes Review - Part II
Discussions
(Paid Plans Only)
Price Chart
(Sign Up to Access)
Insight Stream
Imeik Technology Development (300896.CH) - Superficial Prosperity Hardly Masks Underlying Risks
26 May 2022
The Impact of DRGs Policy on China Medical System
25 May 2022
China Healthcare Weekly (May20)-Lockdown Impact on Macro Economy, Bottom Signal? Rare Disease Policy
22 May 2022
Shanghai Haohai Biological Technology (688366CH)- Diversified Business Layout Doesn't Secure Outlook
19 May 2022
BeiGene Ltd (6160.HK/BGNE.US/688235.CH) - Valuation Remodeling if the TIGIT Project Fails
17 May 2022
Sihuan Pharmaceutical Hldgs (460.HK)- Privatization Rumor, Upside Potential and Concerns on Business
16 May 2022
Bloomage Biotechnology (688363.CH) Vs Imeik Technology (300896.CH) - The Logic and the Outlook
11 Jan 2022
Top
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.54.8
x